[Effect of a new synthetic compound (3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate: I.612) on plasma lipids in patients with type IIa, IIb and IV hyperdyslipidemia].
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D004361:Drug Tolerance; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D009539:Nicotinic Acids; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate
Effetti di un nuovo composto di sintesi (p-clorofenossi-isobutirrato di 3-nicotinoi-lossipropile: I. 612) sui lipidi plasmatici in soggetti affetti da iperdislipidemie di tipo IIa, IIb e IV.